Unknown

Dataset Information

0

C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis.


ABSTRACT: The fibroblast growth factor receptors (FGFRs) are increasingly considered attractive targets for therapeutic cancer intervention due to their roles in tumor metastasis and angiogenesis. Here, we identified a new selective FGFR inhibitor, C11, and assessed its antitumor activities. C11 was a selective FGFR1 inhibitor with an IC50 of 19?nM among a panel of 20 tyrosine kinases. C11 inhibited cell proliferation in various tumors, particularly bladder cancer and breast cancer. C11 also inhibited breast cancer MDA-MB-231 cell migration and invasion via suppression of FGFR1 phosphorylation and its downstream signaling pathway. Suppression of matrix metalloproteinases 2/9 (MMP2/9) was associated with the anti-motility activity of C11. Furthermore, the anti-angiogenesis activity of C11 was verified in endothelial cells and chicken chorioallantoic membranes (CAMs). C11 inhibited the migration and tube formation of HMEC-1 endothelial cells and inhibited angiogenesis in a CAM assay. In sum, C11 is a novel selective FGFR1 inhibitor that exhibits potent activity against breast cancer metastasis and angiogenesis.

SUBMITTER: Chen Z 

PROVIDER: S-EPMC6786402 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis.

Chen Zhuo Z   Tong Lin-Jiang LJ   Tang Bai-You BY   Liu Hong-Yan HY   Wang Xin X   Zhang Tao T   Cao Xian-Wen XW   Chen Yi Y   Li Hong-Lin HL   Qian Xu-Hong XH   Xu Yu-Fang YF   Xie Hua H   Ding Jian J  

Acta pharmacologica Sinica 20181128 6


The fibroblast growth factor receptors (FGFRs) are increasingly considered attractive targets for therapeutic cancer intervention due to their roles in tumor metastasis and angiogenesis. Here, we identified a new selective FGFR inhibitor, C11, and assessed its antitumor activities. C11 was a selective FGFR1 inhibitor with an IC<sub>50</sub> of 19 nM among a panel of 20 tyrosine kinases. C11 inhibited cell proliferation in various tumors, particularly bladder cancer and breast cancer. C11 also in  ...[more]

Similar Datasets

| S-EPMC5880961 | biostudies-literature
| S-EPMC7599145 | biostudies-literature
| S-EPMC4739522 | biostudies-literature
| S-EPMC5081516 | biostudies-literature
| S-EPMC3120092 | biostudies-literature
| S-EPMC8322322 | biostudies-literature
| S-EPMC9909315 | biostudies-literature
| S-EPMC10368285 | biostudies-literature
| S-EPMC2570343 | biostudies-literature
| S-EPMC10657448 | biostudies-literature